Antengene's Xpovio moves close to getting insurance benefits

Korea Biomedical Review

3 May 2024 - Xpovio (selinexor), the first drug launched in Korea by Antengene, has won recognition to receive reimbursement for treating multiple myeloma from the Pharmaceutical Reimbursement Evaluation Committee, surmounting 80% of barriers to getting insurance benefits.

Sanofi's Dupixent (dupilumab) was also recognised as appropriate for expanded coverage for treating severe paediatric atopic dermatitis, while Latuda (lurasidone), an anti-psychotic drug introduced by Bukwang Pharmaceutical, and Erbitux (cetuximab), an anti-cancer drug developed by Merck, passed the Pharmaceutical Reimbursement Evaluation Committee on the condition that they accept drug prices below the Government's proposed valuation.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder